Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922
Recruiting
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of intere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumors
Register for Updates
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
NCT03821129
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Stroke, PFO - Patent Foramen Ovale
Register for Updates
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)
NCT05095727
Recruiting
The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/22/2025
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Glycogen Storage Disease
Register for Updates
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
NCT06821750
Recruiting
The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/20/2025
Locations: Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut
Conditions: Healthy
Register for Updates
Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT04792502
Recruiting
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
Register for Updates
Social Disconnection Study
NCT06705348
Recruiting
The purpose of this research study is to examine the effect of social connectedness on the brain. Study procedures include one Magnetic Resonance Imaging (MRI) or functional Magnetic Resonance Imaging (fMRI) scan, one Positron Emission Tomography (PET) scan, one Magnetic Resonance Spectroscopy (MRS) scan, an electroencephalogram (EEG), and in-person and phone call follow-ups.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/18/2025
Locations: Yale Translational Brain Imaging Program, New Haven, Connecticut
Conditions: Social Disconnection
Register for Updates
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
NCT06050122
Recruiting
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Gorlin Syndrome
Register for Updates
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT05917522
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Yale University, School of Medicine: Transplantation, New Haven, Connecticut
Conditions: Kidney Transplant
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
NCT05907629
Recruiting
CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPT... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Register for Updates
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
NCT05380401
Recruiting
A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
Gender:
ALL
Ages:
36 weeks and below
Trial Updated:
03/17/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Premature
Register for Updates
Pembrolizumab and Brentuximab Vedotin in Subjects with Relapsed/Refractory T-cell Lymphoma
NCT05313243
Recruiting
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have received at least one prior therapy. We hypothesize that this combination is effective and will produce an overall response rate of \~55%. Pembrolizumab and brentuximab will be administered for 16 cycles in subjects with responsive disease. Pembrolizumab w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Yale Smilow Cancer Hospital, New Haven, Connecticut
Conditions: T-Cell Lymphoma
Register for Updates
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
NCT03900468
Recruiting
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Epilepsy
Register for Updates